Blood Brain Barrier Technologies Market Increasing Geriatric Population and Rising Prevalence of Age-Associated Neurological Disorders Contribute Market Growth

The brain is surrounded by protective fluid known as cerebrospinal fluid and a protective membrane called the meninges. Blood brain barrier is another protective element present between the brain's blood vessels, and the cells and other components that together make up brain tissue. The blood brain barrier protects the brain against disease-causing pathogens/toxins that may be present in the blood. It blocks the passage of foreign substances entering the brain tissue. It also blocks the passage of life-saving drugs used to treat neurodegeneration and neuroinflammation events. Thus, the technologies used to deliver drugs across blood brain barrier are different than the technologies used to deliver drugs to other body parts.

Get sample PDF Copy along with table of content at: https://www.theinsightpartners.com/sample/TIPRE00021883/?utm_source=OpenPR&utm_medium=10144

The blood brain barrier technologies market is projected to reach US$ 5,101.94 million by 2028 from US$ 1,041.05 million in 2021; it is estimated to register a CAGR of 25.5% from 2021 to 2028.

The key players operating in the blood brain barrier technologies market include Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company.; Bristol-Myers Squibb Company; Pfizer, Inc.; Johnson and Johnson Services, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Bioasis Technologies Inc.; Abliva AB; and JCR Pharmaceuticals Co., Ltd.

The key companies are adopting organic and inorganic growth strategies to sustain their position in the blood brain barrier technologies market. In October 2020, Bristol Myers Squibb announced the approval of ZEPOSIA (ozanimod) by the Health Canada for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) to decrease the frequency of clinical exacerbations.

Based on technology, the global blood brain barrier technologies market is segmented into bispecific antibody RMT approach, trojan horse approach, increasing permeability, passive diffusion, and other noninvasive BBB technologies. In 2020, the increasing permeability segment held the largest share of the market. However, the reagents segment is expected to register the highest CAGR in the market during 2021–2028. Increased blood brain barrier (BBB) permeability is related with the remodeling of interendothelial junctional complex and gap formation between brain endothelial cells (paracellular pathway), and intensive pinocytotic vesicular transport between the apical and basal side of brain endothelial cells (transcellular path). The growth of the market for the increasing permeability segment can be attributed to the rising focus on research activities to treat many neurological and central nervous system disorders.

According to a preliminary (yet to be peer-reviewed) research study by four Imperial College London academics, as well as other research-based evidence, the COVID-19 infection might cause neurological problems. This viewpoint developed during the first wave of the pandemic. The blood-brain barrier is a semipermeable membrane of endothelial cells that keeps the brain separated from the components and mechanisms of the rest of the body.

Some neurologic disorders such as strokes, neuropathy, Alzheimer's disease, and Parkinson's disease are more common among the elderly populations, and their prevalence is increasing with the elevating life expectancies. According to the WHO, the population is aging rapidly worldwide. During 2015–2050, the world's population of age greater than 60 would nearly double, and its percentage would reach 22% from 12%. Mental and neurological disorders among older adults are likely to account for 6.6% of the total disability-adjusted life year (DALYs) for this age group. Also, as per the same source, ~15% of adults aged 60 and above have a mental disorder.

The blood brain barrier technologies market is segmented on the basis of technology, application, and geography. In terms of technology, the market is segmented into bispecific antibody RMT approach, trojan horse approach, increasing permeability, passive diffusion, and other noninvasive BBB technologies. Based on application, the blood brain barrier technologies market is segmented into Alzheimer’s disease, epilepsy, Parkinson’s disease, multiple sclerosis, Hunter’s syndrome, brain cancer, and others. In terms of geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America.

Buy Complete This Report Copy at: https://www.theinsightpartners.com/buy/TIPRE00021883/?utm_source=OpenPR&utm_medium=10144

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense, Food & beverage, Chemical and Materials, Semiconductors etc.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

This release was published on openPR.